Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

CuraGen Corporation is a biopharmaceutical development company that develops novel therapeutics for the treatment of cancer in the United States and Europe. Its therapeutics is based on novel targets from the human genome that play a role in proven mechanisms underlying disease. The Company's strategy continues to be focused on advancing its pipeline of pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes, promising therapeutics through clinical and preclinical development. CuraGen Corporation was founded in 1991 and is headquartered in Branford, Connecticut. As of October 1, 2009, CuraGen Corporation operates as a subsidiary of Celldex Therapeutics, Inc.

Electrophoretics Ltd., a subsidiary of Proteome Sciences Plc, is a British company located in London. The firm engages in research and experimental development on natural sciences. It was founded in 1992.

Sugen is a biotechnology company that specializes in target-driven drug discovery and development for novel development-stage cancer therapies. It develops new therapeutic approaches to various diseases through its development of small molecule inhibitors that regulate particular signaling pathways. Sugen owns three anti-cancer drugs in clinical development, including novel cytostatic agents and angiogenesis inhibitors. In addition to its current focus in oncology, Sugen is applying its technology platform to identify and validate novel targets for a range of potential clinical applications.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Evotec AS provides marine handling technology to the offshore industry, from design, till engineering, fabrication, installation, commissioning, start up and service. The company is headquartered in Gurskoy, Norway.

Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. They apply their expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, they gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, they are developing proprietary product candidates to treat both orphans as well as more prevalent diseases

Lixte Biotechnology, Inc., a subsidiary of Lixte Biotechnology Holdings, Inc., is an American company. The firm develops pharmaceutical products. It was acquired by SRKP 7, Inc. on June 30, 2006.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Mobility, Inc. provides car sharing services. It operates a fleet of ultra low emission vehicles, gas-electric hybrids and environmentally-friendly sedans, AWD, minivans and sports cars. It serves individuals, companies and public agencies. The company was founded in 1999 and is headquartered in Seattle, WA.